In its second acquisition of the week, Ipsen will take control of Memo Therapeutics and a first-in-class drug for BK polyomavirus, which can cause serious complications in some transplant patients.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI ...